Tesofensine
Overview[edit | edit source]
Tesofensine is a pharmacological compound that has been investigated for its potential use in the treatment of obesity. It functions primarily as a monoamine reuptake inhibitor, affecting the levels of neurotransmitters such as dopamine, norepinephrine, and serotonin in the brain.
Mechanism of Action[edit | edit source]
Tesofensine works by inhibiting the reuptake of key neurotransmitters, which leads to increased levels of these chemicals in the synaptic cleft. This action is believed to enhance satiety and reduce appetite, contributing to weight loss in individuals with obesity. The compound's effect on dopamine and norepinephrine is particularly significant, as these neurotransmitters are involved in the regulation of mood and energy expenditure.
Clinical Development[edit | edit source]
Tesofensine was initially developed for the treatment of neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease. However, during clinical trials, it was observed that patients experienced significant weight loss, leading to a shift in focus towards its potential as an anti-obesity medication.
Clinical Trials[edit | edit source]
Several clinical trials have been conducted to evaluate the efficacy and safety of tesofensine in promoting weight loss. These studies have demonstrated that tesofensine can lead to significant reductions in body weight compared to placebo. However, the trials also highlighted potential side effects, including increased heart rate and blood pressure, which necessitate careful consideration in its use.
Side Effects[edit | edit source]
The use of tesofensine has been associated with several side effects, primarily related to its action on the central nervous system. Common side effects include insomnia, dry mouth, and constipation. More serious cardiovascular effects, such as tachycardia and hypertension, have also been reported, which may limit its use in certain populations.
Future Directions[edit | edit source]
Research into tesofensine continues, with ongoing studies aimed at optimizing its therapeutic profile and minimizing adverse effects. The development of combination therapies and the identification of specific patient populations that may benefit most from tesofensine are areas of active investigation.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
